Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of piperacillin sodium and sulbactam sodium on respiratory function in patients with acute respiratory distress syndrome

Yan Li, Suhang Wang, Jing Zhang, Jie Cao

Department of Respiratory and Critical Care, Tianjin Medical University General Hospital, Tianjin 300052, China;

For correspondence:- Jie Cao Email: zyyhxkcaojie2013@163.com

Accepted: 04 November 2023 Published: 30 November 2023

Citation: Li Y, Wang S, Zhang J, Cao J. Effect of piperacillin sodium and sulbactam sodium on respiratory function in patients with acute respiratory distress syndrome. Trop J Pharm Res 2023; 22(11):2349-2355 doi: 10.4314/tjpr.v22i11.15

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of the combination of piperacillin sodium and sulbactam sodium on respiratory function in patients with acute respiratory distress syndrome (ARDS).

Methods: The clinical data for 151 ARDS patients admitted in Tianjin Hospital of ITCWM Nankai Hospital, Tianjin China from January 2020 to January 2021 were analyzed in this retrospective study. The patients were assigned to two groups based on different treatment regimens. Control group (COG) comprised 77 patients who received basic treatment (mechanical ventilation and drug treatment using oxazolidinones), while 74 patients who received basic treatment together with a combination of piperacillin sodium and sulbactam sodium (4 g of piperacillin and 0.5 g of sulbactam (for adults) through intravenous injection for 2 weeks continuously) were in study group (STG). Respiratory function was assessed in the two groups post-treatment using the basic dyspnea index (BDI) measurement. Mechanical ventilation time, intensive care unit (ICU) stay time and 28-day mortality rate after treatment, were also recorded.

Results: Following treatment, patients in STG had significantly higher levels of partial pressure of arterial oxygen (PaO₂) and oxygenation index (PaO₂/FiO₂), significantly lower partial pressure of carbon dioxide (PaCO₂), markedly lower levels of pentraxin-3 (PTX-3) and procalcitonin (PCT), significantly higher score on BDI scale, and overtly lower mechanical ventilation time and ICU stay time, than COG (p < 0.05).

Conclusion: Piperacillin sodium and sulbactam sodium combination significantly relieves clinical symptoms of ARDS such as breathlessness and chest discomfort in patients, resulting in improved respiratory function. The effectiveness of this combination makes it a potential first-line treatment for further large-scale investigation in ARDS management.

Keywords: Piperacillin sodium, Sulbactam sodium, Acute respiratory distress syndrome (ARDS), Respiratory function